These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28741113)

  • 41. [Direct oral anticoagulant associated bleeding].
    Godier A; Martin AC; Rosencher N; Susen S
    J Mal Vasc; 2016 Jul; 41(4):272-8. PubMed ID: 27297642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
    Nitzki-George D; Wozniak I; Caprini JA
    Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of anticoagulants in elderly patients.
    Bauersachs RM
    Thromb Res; 2012 Feb; 129(2):107-15. PubMed ID: 22014849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anticoagulation in pregnancy and post partum in heat valve diseases, thrombosis or atrial fibrillation: fetal risk versus maternal thromboembolism].
    Gohlke-Bärwolf C
    Z Kardiol; 2001; 90 Suppl 4():49-56. PubMed ID: 11373944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antidotes for the direct oral anticoagulants: What news?
    Galliazzo S; Donadini MP; Ageno W
    Thromb Res; 2018 Apr; 164 Suppl 1():S119-S123. PubMed ID: 29703468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S; Egi M; Kita H; Miyatake Y; Kubota K; Mizobuchi S
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complications of heparin therapy.
    Gervin AS
    Surg Gynecol Obstet; 1975 May; 140(5):789-96. PubMed ID: 1170648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
    Cohen MG; Purdy DA; Rossi JS; Grinfeld LR; Myles SK; Aberle LH; Greenbaum AB; Fry E; Chan MY; Tonkens RM; Zelenkofske S; Alexander JH; Harrington RA; Rusconi CP; Becker RC
    Circulation; 2010 Aug; 122(6):614-22. PubMed ID: 20660806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon?
    Carter CJ
    Postgrad Med; 1996 Jun; 99(6):129-36. PubMed ID: 8668626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use and limitations of unfractionated heparin.
    Krishnaswamy A; Lincoff AM; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):35-40. PubMed ID: 20215909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Management of direct oral anticoagulants for invasive procedures].
    Godier A; Gouin-Thibault I; Rosencher N; Albaladejo P;
    J Mal Vasc; 2015 May; 40(3):173-81. PubMed ID: 25778841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Approaches to diagnosing and managing anticoagulant-related bleeding.
    Goy J; Crowther M
    Semin Thromb Hemost; 2012 Oct; 38(7):702-10. PubMed ID: 23034830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The need to clot: a review of current management strategies for adverse bleeding events with new oral anticoagulants.
    Whalley D; Skappak C; Lang ES
    Minerva Anestesiol; 2014 Jul; 80(7):821-30. PubMed ID: 24226497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.
    Klok FA; Kooiman J; Huisman MV; Konstantinides S; Lankeit M
    Eur Respir J; 2015 Jan; 45(1):201-10. PubMed ID: 25102964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Managing bleeding in anticoagulated patients in the emergency care setting.
    Pollack CV
    J Emerg Med; 2013 Sep; 45(3):467-77. PubMed ID: 23786779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.